Decision Making About Disease-Modifying Treatments for Relapsing-Remitting Multiple Sclerosis: Stated Preferences and Real-World Choices.

Edward J D WebbDavid MeadsIeva EskytėHelen L FordHilary L BekkerJeremy ChatawayGeorge PepperJoachim MartiYasmina OkanSue H PavittKlaus SchmiererAna Manzano

Published in: The patient (2023)

There was variation in which discrete choice experiment attributes correlated with participants' real-world DMT choices. This may indicate patient preferences for treatment efficacy/risk are not adequately taken account of in prescribing. Treatment guidelines must ensure they take into consideration patients' preferences and improve communication around treatment efficacy/risk.

Keyphrases

multiple sclerosis
decision making
primary care
newly diagnosed
end stage renal disease
case report
prognostic factors
white matter
breast cancer risk